Last reviewed · How we verify
Withdrawal of therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Withdrawal of therapy (Withdrawal of therapy) — Royal Brompton & Harefield NHS Foundation Trust. Withdrawal of therapy involves discontinuing an active pharmaceutical treatment to assess disease progression or allow natural resolution.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Withdrawal of therapy TARGET | Withdrawal of therapy | Royal Brompton & Harefield NHS Foundation Trust | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Withdrawal of therapy CI watch — RSS
- Withdrawal of therapy CI watch — Atom
- Withdrawal of therapy CI watch — JSON
- Withdrawal of therapy alone — RSS
Cite this brief
Drug Landscape (2026). Withdrawal of therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/withdrawal-of-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab